ACCOAST: pretreatment with prasugrel in non-ST elevation acute coronary syndrome (NSTE-ACS) offers no benefit and increased bleeding

P2Y12 receptor inhibitors are effective in patients experiencing NSTE-ACS, however, the administration timing is not clear. This study evaluated the administration of prasugrel at the time of diagnosis of ACS or after performing coronary angiography when angioplasty was already decided. 4033 patients were included experiencing an NSTE-ACS troponin positive who had planned angiography between 2 and 48 hours after admission. Patients were randomized to 30 mg of prasugrel (loading dose) at admission versus placebo in the control group and then when angiography was performed, if coronary angioplasty was indicated another 30 mg in the pretreatment branch versus full load of 60 mg in the control group . The primary end point was a composite of cardiovascular death, stroke, urgent revascularization, or need for rescue IIBIIIA.

A week after the procedure, the primary end point, was not significantly different between groups. The TIMI bleeding rate was higher in the pre-treatment group. 

Conclusion

In patients experiencing an NSET-ACS, pre-treatment with prasugrel showed no benefit in terms of ischemic events and increased bleeding risk complications despite the use of radial access or femoral percutaneous closure devices.

4_g_montalescot
G. Montalescot
2014-05-22

Title: Effect of prasugrel pre-treatment strategy  in patients undergoing PCI for NSTEMI: The ACCOAST study

More articles by this author

IBERIAN: appendage occlusion registry

The aim of this study was to observe the rate of thromboembolic and hemorrhagic events in a period of 2 years in 167 patients...

COMPARE II: biolimus eluting stent with biodegradable polymer versus everolimus at 3 years.

This study randomized 2:1 - 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year,...

Bivalirudin superior than heparin beyond the use or not of Glycoprotein inhibitors

Bivalirudin benefits in bleeding events versus heparin plus glycoprotein IIbIIIa inhibitors is clear even though  this benefit has not been fully studied at the...

Meta-analysis confirms the reduction in ischemic events with 2nd generation DES versus BMS

This paper included 5 studies that randomized patients to conventional stent versus chromium cobalt everolimus eluting stent; at 2 years, a significantly lower risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...